Pharmaceutical giant Eli Lilly has significantly expanded its collaboration with artificial intelligence firm Insilico Medicine in a deal potentially worth up to $2.75 billion. The agreement focuses on accelerating the discovery of new oral medicines using advanced AI, building upon a research partnership the two companies began last year.
Under the new terms, Lilly gains an exclusive worldwide license to develop and commercialize certain preclinical drug candidates identified using Insilico's AI platform. In return, Insilico will receive an upfront payment of $115 million and is eligible for substantial milestone payments tied to development, regulatory approval, and commercial success. The cumulative value of these payments could reach approximately $2.75 billion, with Insilico also receiving tiered royalties on future sales of any resulting products.
The core of the partnership is Insilico's AI engine, which Lilly will use to identify novel drug targets and therapies. Insilico's founder and CEO, Alex Zhavoronkov, explained that the technology aims to create comprehensive models of biological systems. "By deploying AI technologies that scale from biomarkers to life models, world models of human and animal life, we can identify multi-purpose targets driving multiple diseases at the same time," Zhavoronkov said. This approach could streamline the traditionally lengthy and costly early-stage drug discovery process by pinpointing promising therapeutic avenues more efficiently.
This deal represents a deepening of a relationship that started with a software licensing agreement in 2023 and evolved into a broader research collaboration by November 2024. The substantial financial commitment underscores a growing trend in the pharmaceutical industry, where major players are investing heavily in AI to bolster their pipelines and tackle complex diseases through new biological insights.
The expanded alliance signals a strong vote of confidence in AI-driven discovery methods. While the therapies involved are still in preclinical stages, the partnership aims to translate cutting-edge computational biology into tangible treatments for patients. The next steps will involve rigorous testing and development of the licensed candidates, with the hope that this fusion of AI and pharmaceutical expertise will yield new, effective medicines in the coming years.